FIG. 6.

Chronic MHV-induced demyelinating disease is not affected following anti-IL-23p19 or anti-IL-12/23p40 treatment. Histologic scoring of the severity of white matter damage to the spinal cords of mice from anti-IL-23p19 (A) and anti-IL-12/23p40 (B) treatment groups indicated no differences in disease severity at either day 21 or 28 post-infection compared to control treated mice. Data were derived from a minimum of three mice per antibody treatment group for each time point, and represent at least two independent experiments. Representative luxol fast blue staining of spinal cords (×100) revealed no difference in the severity of demyelination in anti-IL-23p19 (A) and anti-IL-12/23p40 (B) treated mice when compared to control treated mice at day 21 post-infection. Data are presented as average SEM.